

# Montelukast moderately decreased asthma symptoms in children with persistent asthma

Knorr B, Franchi LM, Bisgaard H, et al. *Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics* 2001 Sep;108:e48.

Source of funding:  
Merck Research  
Laboratories.

For correspondence:  
Dr B Knorr,  
Respiratory & Allergy,  
Merck Research  
Laboratories, Rahway,  
NJ, USA.

**QUESTION:** In children with persistent asthma, is montelukast a well tolerated and effective therapeutic option?

## Design

Randomised [allocation concealed\*]†, blinded (patients, clinicians, and [data collectors]‡),\* placebo controlled trial with 12 weeks of follow up.

## Setting

93 centres in Africa, Australia, Europe, North America, and South America.

## Patients

689 children who were 2 to 5 years of age (mean age 4 y, 59% boys, 56% white), had  $\geq 3$  episodes of asthma symptoms in the previous year, had a total asthma symptom score  $\geq 1$  (of 24) for  $\geq 8$  days during the 2 week placebo baseline period, and used  $\beta$  agonists for  $\geq 8$  days during the placebo baseline period. Exclusion criteria included asthma intubation and emergency department treatment or admission to hospital for asthma within 1 month before the study. Follow up ranged from 98% to 100% for safety and from 81% to 96% for other outcomes.

## Intervention

Patients were allocated to montelukast, 4 mg chewable tablet (n=461), or to placebo tablet (n=228). Tablets were given once daily at bedtime for 12 weeks.

## Main outcome measures

Safety, asthma symptoms, and days with  $\beta$  agonist use and without asthma.

## Main results

Analysis was by intention to treat for [safety]† and effectiveness end points. The montelukast and placebo groups did not differ for frequency of overall adverse effects or individual adverse effects except for asthma, which occurred more frequently in the placebo group (30% v 38%, difference 8.0%, 95% CI 0.18 to 16). The groups did not differ for discontinuation of treatment because of adverse effects (3.5% v 3.1% [p=0.999]‡). Groups did not differ for  $\geq 1$  laboratory adverse effect (3.6% v 5.4% [p=0.31]‡). Montelukast decreased asthma symptom scores (table) and days with  $\beta$  agonist use (49% v 55%, p=0.001), and increased days without asthma (34% v 28%, p=0.002) more than did placebo.

## Conclusion

In children with persistent asthma, montelukast was well tolerated, decreased asthma symptom scores and  $\beta$  agonist use, and increased days without asthma.

\*See glossary.

†Information provided by author.

‡p Values provided by author.

## Montelukast v placebo at 12 weeks in children with persistent asthma

Outcomes§	Mean decrease in score from baseline		Least-square mean difference (CI)
	Montelukast	Placebo	
Overall daytime asthma symptom score	0.37	0.26	0.12 (0.04 to 0.20)
Overnight asthma symptom score	0.46	0.37	0.11 (0.01 to 0.21)

§No symptoms = 0; severe symptoms = 4 or 5.

## COMMENTARY

The well conducted multicentre study by Knorr *et al* showed that montelukast led to greater improvement in asthma symptoms and control than placebo. Because montelukast was compared with placebo, more studies are needed to clarify its effectiveness when compared or combined with other anti-inflammatory medications. One randomised controlled trial (RCT) in children showed that montelukast plus budesonide improved asthma control better than budesonide alone.<sup>1</sup> Another RCT in adults also showed a treatment benefit after 16 weeks of beclomethasone plus montelukast.<sup>2</sup>

For safety, caution is always needed when using tablets in young children. The American Academy of Pediatrics notes that safe swallowing can be difficult for young children for reasons of anatomy, experience, and judgment.<sup>3</sup> However, many chewable tablets are approved for use in children  $\geq 2$  years of age.<sup>4</sup> The study by Knorr *et al* had a 90% probability of detecting an adverse drug reaction (ADR) of 7.8% in the montelukast group and 1% in the placebo group. However, the likelihood of detecting a less common ADR would be about 5% for an event occurring in 1 in 10 000 patients.<sup>5</sup> Thus, rare ADRs can only be determined by post-marketing surveillance.

What are the clinical implications? The National Asthma Education and Prevention programme expert panel has recommended leukotriene modifiers for persistent asthma in children  $> 5$  years of age.<sup>6</sup> The study by Knorr *et al* now adds evidence for its effectiveness in younger children.

Lynnette J Mazur, MD, MPH  
University of Texas—Houston Health Science Center  
Houston, Texas, USA

- 1 Simons FE, Villa JR, Lee BW, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. *J Pediatr* 2001;138:694–8.
- 2 Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. *Am J Respir Crit Care Med* 1999;160:1862–8.
- 3 Widome MD, editor. *Injury prevention and control for children and youth*. 3rd edition. Elk Grove Village, IL: The Academy, 1997.
- 4 Michele TM, Knorr B, Vadas EB, et al. Safety of chewable tablets in children. *J Asthma* 2002 (in press).
- 5 Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. *JAMA* 1983;249:1743–5.
- 6 *Guidelines for the diagnosis and management of asthma: expert panel report 2*. Bethesda, MD: National Heart, Lung, and Blood Institute, 1997 (<http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf>).